We performed the current trial to evaluate whether 12- month metformin therapy improves vascular stiffness in patients with NAFLD and to assess if this improvement is associated with change in glucose control, insulin resistance or circulating adiponectin. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.